And the Beat Goes On
November 2025 editorial review highlights several key advances in heart failure care
-
By
-
Conexiant News Staff
-
January 12, 2026
-
Clinical Scorecard: And the Beat Goes On
At a Glance
| Category | Detail |
|---|
| Condition | Heart Failure |
| Key Mechanisms | Intersection of oncology, advanced imaging, and systems-based management |
| Target Population | Patients with heart failure, particularly those with a history of malignancy |
| Care Setting | Multidisciplinary care settings, including high-volume centers |
Key Highlights
- Nearly 20% of heart failure patients have a history of cancer diagnosed over 2 years prior to HF onset.
- Patients with HF and prior malignancy experience higher all-cause mortality.
- Echocardiographic phenotype in advanced cancer shows reduced left ventricular mass and HF-like symptoms.
- Low-dose sacubitril/valsartan may prevent cancer therapy-related cardiac dysfunction.
- High-volume centers are associated with lower in-hospital mortality in cardiogenic shock.
Guideline-Based Recommendations
Diagnosis
- Integrated cardio-oncology care is essential for patients with a history of malignancy.
Management
- Guideline-directed medical therapy should be prioritized for HF patients with prior malignancy.
Monitoring & Follow-up
- Longitudinal assessment of left ventricular mass may be clinically relevant.
Risks
- Higher rates of noncardiovascular death in HF patients with a history of cancer.
Patient & Prescribing Data
Patients receiving adjuvant therapy for early breast cancer
Low-dose sacubitril/valsartan shows promise in preventing cardiac dysfunction.
Clinical Best Practices
- Implement multidisciplinary care approaches for heart failure management.
- Utilize advanced imaging techniques for refined phenotyping of heart failure patients.
References
